The pharmacy already has a public acquisition file.
The counter still charges a number that may not sit next to it.
That gap is the product.
The idea mills keep minting a pharmacy chatbot, a coupon-clipper app, and an rxcheck.ai.
Three names.
One object.
A register receipt, or the sticker on the bag, that does not sit next to the acquisition file the Centers for Medicare and Medicaid Services already publishes every week, or next to the maximum fair price file that took effect on January 1, 2026.
Greg Isenberg’s stream and the daily micro-SaaS accounts keep splitting the same reader.
One post wants a refund radar that studies why people ask for money back.
Another wants a bill auditor that gets paid only when the client saves.
A third wants a photo of a medical bill dropped into a chat, with a letter on the other side.
Cute.
Wrong cut if you stop at the chat.
The customer does not wake up wanting a PBM explainer.
They wake up because the bag was $47 and the same capsule was $9 at the pharmacy across the street, or because a Part D claim in 2026 still does not look like the price CMS already posted.
Why this year, not a white paper
Two public files moved from “someone could look it up” to “a stranger can photograph a receipt this week.”
The first is NADAC, the National Average Drug Acquisition Cost.
CMS posts it weekly on data.medicaid.gov.
It is a survey of what retail pharmacies pay wholesalers for a drug, net of prompt-pay discounts, not the price on the register.
A markup over that file is not automatically a rip-off.
A pharmacy has rent, a pharmacist, and a dispensing fee.
The product is the join, not the sermon.
The Federal Trade Commission made the scale of the join hard to ignore.
On January 14, 2025 the Commission published its second interim staff report on prescription-drug middlemen.
Staff found that the Big Three — Caremark, Express Scripts, and OptumRx — marked up numerous specialty generic drugs dispensed at affiliated pharmacies by hundreds and thousands of percent.
Those affiliated pharmacies generated more than $7.3 billion in dispensing revenue in excess of estimated acquisition cost, measured by NADAC, from 2017 to 2022.
That excess revenue grew at a compound annual rate of 42 percent from 2017 to 2021.
The top 10 specialty generics accounted for $6.2 billion of it, 85 percent of the total in the study window.
The second file is newer, and it is the reason the wedge is this quarter rather than a 2027 roadmap.
CMS published negotiated prices — the statute calls them maximum fair prices — for the first 10 Part D drugs on August 15, 2024.
Those prices took effect January 1, 2026.
The same fact sheet said that if the agreed prices had been in effect in 2023, net covered prescription-drug spending on those drugs would have been about $6 billion lower, 22 percent.
About 9 million people with Medicare use at least one of the 10.
Under the projected defined standard benefit, CMS estimated $1.5 billion in out-of-pocket savings for people with Part D in 2026.
A participating manufacturer has to make the negotiated price available to eligible people and to the pharmacies that dispense the drug.
The file is public.
The receipt is in the bag.
Almost nobody puts them on the same page before the card is charged.
Two primitives, one wedge
Primitive one is photo-and-PDF review.
The mills have been shipping receipt readers for months.
The input here is the thing already in the bag.
Register receipt.
Bag label.
Part D explanation of benefits, if one exists.
NDC if it printed.
Drug name and strength if it did not.
Quantity.
Amount paid.
Date.
Pharmacy name.
Cash, coupon, or plan.
Primitive two is the public file join.
NADAC for the NDC in the week of the fill.
If the drug is one of the first ten and the payer is Part D, the maximum fair price for that NDC and supply.
The output is three words, not a coach.
Match.
Mismatch.
File too thin.
File too thin is a real answer.
NADAC does not cover every branded specialty the way a coupon site pretends to.
A maximum fair price is not a cash price for a person who is not in Part D.
Saying so is the product working.
The wedge is a free checker.
Not a platform.
No account for the first answer.
Photograph the receipt.
Thirty seconds later: above the weekly acquisition file by this much, above the 2026 price file, or not enough on the page to say.
If you cannot get a stranger to photograph one receipt this week, you do not have a company.
You have a policy thread.
What the checker is not allowed to do
It does not tell anyone to stop a drug, split a tablet, or switch pharmacies on a clinical claim.
It does not file an appeal.
It does not move money.
A mismatch on a specialty generic can be a plan design, a spread, a coupon that already fired, or a bad read of the NDC.
The model drafts the comparison.
A person owns the send.
Anything that leaves the building — a note to the pharmacy, a Part D inquiry, a complaint to a state board — needs a human signer who has seen the receipt, the file row, and the sentence that will be sent.
Contingency is fine after that signature, and only after a confirmed mismatch.
Charge them when the file proves the gap, or do not charge them.
Do not sell a subscription to a dashboard of adherence.
The map is the company
The first hundred receipts are a demo.
The ten thousandth is a labeled map of counter price versus acquisition cost, and versus the 2026 price file, by NDC, chain, and ZIP.
That map is the moat.
Coupon sites already show a cash offer.
They do not keep the pair: what this person was charged, what the weekly file said that week, and whether the Part D claim sat on the posted maximum fair price.
A plan sponsor, a state Medicaid shop, or a local reporter will pay for the pair once it is boring and repeatable.
They will not pay for another chatbot that explains formularies.
Start narrow.
Week one and two: one checker.
Photo or PDF in.
Cash generics with a stable NADAC row.
One state.
No account.
Week three and four: the ten Part D drugs, and only the comparison to the posted price.
A draft inquiry pack with the file row cited, held until a person signs.
Do not start with oncology markups and a letter to a PBM.
That is how the first customer becomes an exhibit.
Why this cut, not the last one
The leakage essay was tariffs, seats, and subscriptions.
The rebate essay was a nameplate.
The recall essay was a label.
The short-pay essay was a contractor packet.
The bill essay was an EOB against a hospital file.
The tax essay was a notice against the roll.
The utility essay was a statement against a filed tariff.
The housing essay was a unit against a score.
The delay essay was an itinerary against a cause code.
The HOA essay was an assessment against a study.
The 401(k) essay was a fee against a filing.
This one is the bag version of the same pair: a document the customer already holds, plus a file the agency was required to publish, joined while the first negotiated prices are still new and the specialty-generic markup is already on a public record.
The hospital file was a chargemaster.
This file is an acquisition cost and a negotiated price.
Different object.
Same habit.
Someone will own the labeled map of charged versus filed.
The mills will keep proposing a new .ai name for each receipt.
Ignore the names.
Join the line.
Keep the map.
Will Tygart — Tygart Media.
This is the idea-mill series.
